Literature DB >> 14730343

Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation.

M Ortega1, M Rovira, M Almela, J P de la Bellacasa, E Carreras, J Mensa.   

Abstract

The aim of this study was to evaluate the usefulness of C-reactive protein (CRP) monitoring in the differential diagnosis and prognosis of febrile neutropenic episodes in hematopoietic cell transplantation (HCT). In all, 100 patients were enrolled in the study. The CRP was determined in serum every 48 h from admission until resolution of the febrile episode. All patients presented with fever during the post-HCT neutropenic period. The febrile episodes were classified as microbiologically documented infection in 32 cases, clinically documented infection in 27 patients and fever of unknown origin in 41 patients. The mean CRP values on the first day of fever in these three groups were similar (NS). On the fifth day of antibiotic treatment, 50 patients remained pyrexial. Of these, 41 improved with modifications of antibiotherapy (mean CRP: 9.5 mg/dl; standard deviation (s.d.): 6.2) and nine died, five due to an infectious etiology (CRP: 21 mg/dl; s.d.: 4.4; P<0.003) and four from other causes (CRP: 11 mg/dl; s.d.: 3.4). On multivariate analysis, the CRP on the fifth day of treatment was an independent prognostic factor for fatal outcome. We conclude that persistent elevation of the CRP is an independent factor predicting a fatal outcome in patients who remain febrile on the fifth day of antibiotherapy during neutropenic febrile episodes post-HCT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730343     DOI: 10.1038/sj.bmt.1704409

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?

Authors:  K S R Massaro; R Macedo; B S de Castro; F Dulley; M S Oliveira; M A S Yasuda; A S Levin; S F Costa
Journal:  Infection       Date:  2014-09-30       Impact factor: 3.553

2.  C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.

Authors:  Juan F Combariza; Milton Lombana; Luis E Pino; Marcos Arango
Journal:  Support Care Cancer       Date:  2014-10-02       Impact factor: 3.603

3.  Diagnostic value of C-reactive protein in discriminating fungal from nonfungal pulmonary infiltrates in patients with hematologic malignancies.

Authors:  Massimo Offidani; Laura Corvatta; Lara Malerba; Maria-Novella Piersantelli; Esther Manso; Pietro Leoni
Journal:  Support Care Cancer       Date:  2006-02-15       Impact factor: 3.603

4.  C-reactive protein in critically ill cancer patients with sepsis: influence of neutropenia.

Authors:  Pedro Póvoa; Vicente Ces Souza-Dantas; Márcio Soares; JorgeI F Salluh
Journal:  Crit Care       Date:  2011-05-19       Impact factor: 9.097

5.  Predictors of Outcome and Severity in Adult Filipino Patients with Febrile Neutropenia.

Authors:  Marc Gregory Y Yu; Ralph Elvi M Villalobos; Ma Jasmin Marinela C Juan-Bartolome; Regina P Berba
Journal:  Adv Hematol       Date:  2015-09-03

Review 6.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673

7.  C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Authors:  Vidya Kollu; Sarah L Mott; Rafiullah Khan; Umar Farooq; Yogesh Jethava; Ince Dilek; Guido Tricot
Journal:  Cureus       Date:  2018-07-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.